News Releases | CSL

Skip to main content

Global Selector
Newsroom
Partnering
Contact

We Are CSL

Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
Read the Stories

CSL consists of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Our Businesses and Products
Patients & Public Health

Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
CSL Behring: Rare & Serious Diseases

Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
CSL Seqirus: Vaccines
R&D

R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
R&D Capabilities

One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
Awards, Grants and Initiatives
Sustainability

Sustainability

Environment

Social

Sustainable Workforce

Governance

Data and Reporting Centre

As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Learn About Our Targets

Along with our sustainability strategy, CSLâ€™s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
Supporting Our Communities
Careers

At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Read About Our DE&I

Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Early Careers at CSL
Investors

Search

Popular search terms:

Clinical Trials
Careers at CSL
Watch: Protecting Yourself from COVID-19 and Flu
Our Products

We Are CSL
- Our Businesses and Products
- Corporate Governance
Patients & Public Health
- Rare & Serious Diseases
- Iron Deficiency
- Nephrology
- Vaccines
- Patient Support & Organizations
R&D
- Clinical Studies at CSL
Sustainability
- Environment
- Social
- Sustainable Workforce
- Governance
- Data and Reporting Centre
Careers
- Early Careers at CSL
Global Selector

CSL
Global Newsroom
News Releases

Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases

PDF VERSION OF PRESS RELEASE

Back to overview of Press Releases

14-02-2017

159 KB

Get our latest news releases in your inbox

* Required Fields

* Email

* First Name

* Last Name

* Country

Terms of Use Cookie Policy Privacy Policy Accessibility Statement Sitemap

Terms of Use
Cookie Policy
Privacy Policy
Accessibility Statement
Sitemap

© 2023 CSL, All Rights Reserved

Corporate

CSL Limited (CSL Behring's Parent Company)

CSL Behring Worldwide

Americas

Argentina
Brazil
Canada
Chile
CSL Behring Global
CSL Plasma - US (CSL Behring Subsidiary)
Mexico

Asia Pacific

Australia
China
Japan
Korea
Singapore
Taiwan

Europe

Austria
Belgium and Luxembourg
CSL Plasma - Germany (CSL Behring Subsidiary)
CSL Plasma - Hungary (CSL Behring Subsidiary)
Czech Republic
Denmark
Finland
France
Germany
Greece
Hungary
Italy
Netherlands
Norway
Poland
Russia
Slovakia
Spain
Sweden
Switzerland
Turkey
United Kingdom